Technologies

BostonGene Receives Frost & Sullivan’s 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms

  • by

​ Recognition highlights BostonGene’s leadership in improving drug development decisions,reducing risk and accelerating patient impact SAN ANTONIO, May 5, 2026 /PRNewswire/ — Frost & Sullivan is pleased to announce that BostonGene has been recognized as the 2026… Read More »BostonGene Receives Frost & Sullivan’s 2026 Global Company of the Year for Advancing in AI-Driven Multimodal Oncology Platforms